OR WAIT null SECS
December 04, 2021
"The results of this trial impacted practice globally,” says Michael J. Morris, MD.
“For most men, we can identify the specific site or sites of recurrence, and thereby use a more directed therapy that specifically targets the abnormal sites,” says Gerald L. Andriole, MD.
December 03, 2021
“The good news for patients is that the survival and radiographic progression-free survival [were] substantially improved in all subsets,” says Andrew J. Armstrong, MD, MSc.
"It’s an important topic to debate,” says Scott E. Eggener, MD.
“There are so many advances in prostate cancer, many of which are actually targeted,” says Alicia K. Morgans, MD, MPH.
A secondary analysis of 2 treatment alteration studies demonstrated that 18F-fluciclovine PET/CT scans play a pivotal role in determining if androgen deprivation therapy is appropriate for patients with prostate cancer.
December 02, 2021
The study included patients who were Hispanic and from the south Florida region, which was not included in previous studies.
“Overall, my take is that even with an intense PSMA-targeted radionuclide regimen, I think the chance of a response… at least by PSA, is higher with stronger baseline PSMA imaging,” says Scott T. Tagawa, MD, MS, FACP.
Eggener addresses the NCCN’s reversal on its controversial decision to remove the word “preferred” from its guideline on active surveillance for low-risk prostate cancer.
"We sought to conduct a National Cancer Database analysis evaluating the impact of the extent of lymphadenectomy on survival outcomes for patients presenting with intermediate- and high-risk prostate cancer,” said Furkan Dursun, MD.
